Simnova raises $60M Series B to advance cell therapy pipeline

What's the deal? Simnova, a Chinese immune cell therapy developer, has raised close to 400,000,000 CNY (roughly $60 million) in a Series B round. Foundation Capital, Qianji CapitalDealroom has a profile for this one. Try Dealroom →, and Pudong Venture CapitalDealroom has a profile for this one. Try Dealroom → co-led the round.

Who else joined? Zhangke Herun and Oriza HoldingsDealroom has a profile for this one. Try Dealroom → participated as new backers, while existing investor Youshan CapitalDealroom has a profile for this one. Try Dealroom → added to its stake. The mix of institutional names signals broad investor confidence in the company's approach.

What's the endgame? Simnova develops immune cell therapies. It will use the funds to speed confirmatory clinical studies for SNC103, its universal CAR-NK lead program, and to push its in vivo CAR-T platform SNC116 into registrational clinical development.

The signal: The round reflects continued investor appetite for next-generation cell therapies, particularly off-the-shelf and in vivo approaches that aim to simplify manufacturing and expand patient access.

Image credit: Generated with Gemini